GlassScriptPhysician profile
Trishna Patel
NPI 1255020483
$7,345.09
in general payments reported to CMS, 2019-2025
23 companies · $2,990 in 2025
The $2,990 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $620 · 2024: $3,735 · 2025: $2,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,072 · Travel and Lodging: $1,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,072.36 |
| Travel and Lodging | $1,272.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $2,485.96 | 2024-2025 | Evoke |
| Abbvie INC. | $1,231.47 | 2023-2025 | |
| Abbott Laboratories | $830.62 | 2024-2025 | Proclaim, Eterna |
| Collegium Pharmaceutical, INC. | $580.79 | 2023-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $507.41 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $390.80 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $261.33 | 2023-2024 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.95 | 2023-2025 | Relistor |
| Globus Medical, INC. | $217.95 | 2025 | Senza |
| Lundbeck LLC | $152.58 | 2024 | Vyepti |
| Lilly USA, LLC | $86.72 | 2023-2024 | Emgality, Zepbound |
| Orexo US, INC. | $74.87 | 2024 | Zubsolv |
| Foundation Fusion Solutions, LLC | $68.38 | 2024 | |
| Atland Pharmaceuticals, LLC | $30.63 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Amgen INC. | $27.90 | 2024 | Aimovig |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $24.43 | 2024 | |
| Vertos Medical, INC. | $23.96 | 2024 | Mild Device Kit |
| Idorsia Pharmaceuticals US INC | $20.63 | 2023 | Quviviq |
| Averitas Pharma INC. | $20.13 | 2024 | Qutenza |
| Tonix Medicines, INC. | $19.73 | 2024 | Zembrace Symtouch |
| Azurity Pharmaceuticals, INC. | $19.33 | 2023 | Horizant |
| Kowa Pharmaceuticals America, INC. | $16.72 | 2023 | Seglentis |
| Painteq LLC | $14.80 | 2024 | Painteq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trishna Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.